Nobivac Tricat Trio 10 doses (no solvent)

Target species Cats Indications for use Active immunisation of cats: -to reduce the clinical signs caused by infection with feline calicivirus (FCV) and feline herpes virus type 1 (FHV), -to prevent the clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPLV). Onset of immunity: for FCV and FHV: 4 weeks; for FPLV: 3 weeks. Duration of immunity: for FCV and FHV: 1 year, for FPLV: 3 years. Contraindications See section “Use during pregnancy”. Special warnings for each target species Maternal antibodies, which may persist up to the age of 9-12 weeks, can have a negative influence on the efficacy of vaccination. In the presence of maternal antibodies, vaccination may not completely prevent the clinical signs, leucopenia and virus excretion following an FPLV infection. In such cases where a relatively high level of maternally derived antibodies is expected, the vaccination schedule should be planned accordingly. Special precautions for use Only healthy animals should be vaccinated. Operator warnings In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Adverse reactions A slight painful swelling may be observed at the injection site for 1-2 days. A slight transient rise in body temperature (up to 40°C) may occur for 1-2 days. In some cases sneezing, coughing, nasal discharge, and a slight dullness or reduced appetite may be observed for up to 2 days post vaccination. In very rare cases, the vaccine may cause hypersensitivity reactions (pruritus, dyspnoea, vomiting, diarrhoea and collapse). Use during pregnancy or lactation Do not use during pregnancy or lactation, as the product has not been tested in pregnant or lactating queens. Live FPL virus can cause reproductive problems in pregnant queens and birth defects in the progeny. Interactions No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.